Board and Committee Changes Released : 06.05.2021 17:50 RNS Number : 8440X GlaxoSmithKline PLC 06 May 2021 GlaxoSmithKline plc GSK announces changes to its Board and Committees GlaxoSmithKline plc today announces the following changes to its Board and Committee membership effective 6 May 2021. As previously announced, Dr Anne Beal has joined the Board as an Independent Non-Executive Director. She has been appointed a member of the Corporate Responsibility Committee. In addition, Charles Bancroft has been appointed a member of the Nominations & Corporate Governance and Science Committees. These appointments are in addition to his role as Chairman of the Audit & Risk Committee and membership of the Transformation & Separation Committee. Note 1. From 6 May 2021 the Board of GSK comprises Sir Jonathan Symonds Non-Executive Chairman Emma Walmsley Chief Executive Officer Iain Mackay Chief Financial Officer Dr Hal Barron Chief Scientific Officer and President, R&D Vindi Banga Senior Independent Non-Executive Director Charles Bancroft Independent Non-Executive Director Dr Anne Beal Independent Non-Executive Director Dr Vivienne Cox Independent Non-Executive Director Lynn Elsenhans Independent Non-Executive Director Dr Jesse Goodman Independent Non-Executive Director Dr Laurie Glimcher Independent Non-Executive Director Urs Rohner Independent Non-Executive Director V A Whyte Company Secretary 6 May 2021 This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
[email protected] or visit www.rns.com.